Prices are closing data as of 2026-11-09, not real-time quotes. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for Royalty Pharma plc?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2018–2025
Key Multi-Year Facts
- Revenue moved from $1.79B in FY2018 to $2.38B in FY2025 (7-year CAGR +4.1%).
- Profitable in every fiscal year across 2018–2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (USD B) | 2.29 | 2.24 | 2.35 | 2.26 | 2.38 |
| YoY | 7.9% | -2.3% | 5.2% | -3.9% | 5.1% |
| Net Income (USD B) | 0.62 | 0.04 | 1.13 | 0.86 | 0.77 |
| YoY | -36.4% | -93.1% | 2549.5% | -24.3% | -10.2% |
| Operating Cash Flow (USD B) | 2.02 | 2.14 | 2.99 | 2.77 | 2.49 |
| Net Margin | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| Debt-to-Assets | 41.5% | 43.3% | 38.4% | 43.2% | 50.5% |
Show all 8 fiscal years
| Fiscal Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD B) | 1.79 | 1.81 | 2.12 | 2.29 | 2.24 | 2.35 | 2.26 | 2.38 |
| YoY | — | 1.1% | 17.0% | 7.9% | -2.3% | 5.2% | -3.9% | 5.1% |
| Net Income (USD B) | 1.38 | 2.35 | 0.98 | 0.62 | 0.04 | 1.13 | 0.86 | 0.77 |
| YoY | — | 70.5% | -58.5% | -36.4% | -93.1% | 2549.5% | -24.3% | -10.2% |
| Operating Cash Flow (USD B) | 1.62 | 1.67 | 2.03 | 2.02 | 2.14 | 2.99 | 2.77 | 2.49 |
| Net Margin | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| Debt-to-Assets | — | 50.7% | 38.2% | 41.5% | 43.3% | 38.4% | 43.2% | 50.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: SEC XBRL filings, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-10
Rules-based screening using SEC XBRL financial data and 8-K/NT material event filings (no AI opinions).
Items Flagged for Review
-
Watch
Short-Term Debt CoverageSolvency
Cash $0.51B, short-term debt $1.00B (0.52x)
Quarterly (2026-09-30) · What is this?
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividend HistoryFY2018–2025
Paid dividends in 5 of the latest 8 fiscal years.
| Fiscal Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| DPS (USD) | — | — | $0.30 | $0.68 | $0.76 | $0.80 | $0.84 | — |
Per-share amounts are as originally declared in annual filings and are not retroactively adjusted for subsequent splits. See U.S. high dividend stocks.
More U.S. data: 500 largest U.S. companies · U.S. high dividend stocks · Is the stock market open today?
Compiled mechanically from public filings and market quotes (data as of 2026-11-10). For informational purposes only, not investment advice.